



# ZEUS ELISA Test System

*Borrelia VlsE-1/pepC10 IgG/IgM*



**ZEUS Scientific**  
Diagnostic innovation. Worldwide application.

# Test with confidence

Lyme disease is the most common tick-borne disease in the Northern Hemisphere and is caused by infection with *Borrelia burgdorferi*, a spirochetal bacteria. Lyme disease occurs in stages, often with intervening latent periods and with different clinical manifestations. Early diagnosis of Lyme disease and subsequent treatment with antibiotics can, in most cases, eliminate infection and symptoms. However, delayed or inadequate treatment can lead to more serious symptoms such as heart abnormalities, arthritis or CNS syndromes.

In recent years advancements in the identification of antigens to assist with the diagnosis of Lyme disease has led to the use of antigens which provide increased clinical sensitivity and specificity. Using a combination of VlsE1 and pepC10 antigens, the ZEUS *Borrelia* VlsE1/pepC10 IgG/IgM ELISA provides laboratories a polyvalent test system with increased sensitivity for detecting early Lyme disease and increased specificity compared to systems which only detect antigen responses to single peptides such as C6, or single antigen assay systems.




ZEUS ELISA™



less false negatives



earlier detection



dual antigens

# We've made Lyme disease harder to miss.

Our new *Borrelia* ELISA test system uses a combination of ***VisE-1*** and ***pepC10*** antigens to test for Lyme Borreliosis simultaneously in the same assay. It's an approach that increases specificity and sensitivity, and lets you test with greater confidence at all stages of Lyme disease.



# Product benefits

## More specific, more sensitive, more reliable <sup>(1)</sup>

- Evidence suggests the combination of VlsE-1/pepC10 antigens is more sensitive than C6 peptide alone for detecting early acute manifestations and IgG responses in patients with neurological disease
- Highly purified and specific antigens provide equivalent sensitivity to that of two-tiered testing for patients with diverse manifestations of Lyme disease
- Specificity of antigen combination reduces false positives and cross reactivity to other bacteria and antibodies compared to single antigen or whole cell systems

### References


1. *R.M. Bacon et al.* Improved Serological Testing for Lyme Disease. JID 2003; 187:1187-1199

## Product features

- Uses recombinant VlsE-1 protein and synthetic pepC10 peptide in combination for simultaneous detection of IgG and IgM in the same assay
- Highly purified and specific antigens yield excellent assay reproducibility
- Automation friendly, can be run manually and compatible with a number of ELISA automation platforms
- Utilizes ZEUS' universal ELISA procedure and common reagents for maximum efficiency and reliability
- Test with confidence: features SAv<sup>™</sup> Diluent, a sample addition verification system


## Comparison with CDC Panel

**Study A:** 39 patient samples from the CDC, clinically diagnosed with Borreliosis and categorized by “time since diagnosis.”



## Comparison of Clinical Sensitivity with Western Blot

**Study B:** 100 patient samples, clinically diagnosed with Borreliosis. Symptoms included tick exposure, EM rash, myalgias, arthralgias, headache or stiff neck.



## Ordering Information

Catalog No:	Product Description
3Z9661	Borrelia VlsE1/pepC10 IgG/IgM Test System (96 tests)
3Z9661B	Borrelia VlsE1/pepC10 IgG/IgM Test System (480 tests)

## Related Products

Catalog No:	Product Description
FA9531GM	IFA Borrelia burgdorferi IgG/IgM Test System 10 x 10 wells
3Z9651G	Borrelia burgdorferi IgG ELISA Test System (96 tests)
3Z9651M	Borrelia burgdorferi IgM ELISA Test System (96 tests)

## Distributor Information

To learn more, visit [www.zeusscientific.com/lyme](http://www.zeusscientific.com/lyme)

